The agreement will expand funding by up to $472 million in part to support the Phase 3 study of mRNA-1273, the company's COVID-19 vaccine. This funding expands on Moderna's previous agreement with BARDA for $483 million.
Pharmaceutical and biotech companies around the world are in hot pursuit to develop a safe and effective vaccine for COVID-19. First let’s look at a quick primer of how vaccines work in general.
Moderna today announced progress on late-stage development of mRNA-1273, the Company’s mRNA vaccine candidate against COVID-19.
For key manufacturers, numbers are beginning to reflect the potential financial impact of vaccine development. Hopeful investors have surged the price of Moderna, whose press releases are dominating the news on vaccine development in the US. Recently....
Early on in the race to develop a vaccine for COVID-19, a handful of brave volunteers opted to take an experimental version of the vaccine.